- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
448
Companies which are more than 50% undervalued based on analyst price target.
448 companies
COMPASS Pathways
Market Cap: US$549.7m
Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
CMPS
US$5.77
7D
4.2%
1Y
2.3%
Corvus Pharmaceuticals
Market Cap: US$549.2m
A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
CRVS
US$7.26
7D
12.0%
1Y
37.5%
Verastem
Market Cap: US$543.4m
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
VSTM
US$8.80
7D
2.2%
1Y
202.4%
Bicycle Therapeutics
Market Cap: US$536.4m
A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
BCYC
US$8.33
7D
9.9%
1Y
-63.1%
Organogenesis Holdings
Market Cap: US$535.3m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$4.24
7D
-13.5%
1Y
48.8%
Esperion Therapeutics
Market Cap: US$534.3m
A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
ESPR
US$2.90
7D
19.3%
1Y
59.3%
Zevra Therapeutics
Market Cap: US$533.8m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$9.43
7D
5.4%
1Y
32.4%
CytomX Therapeutics
Market Cap: US$526.1m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$3.35
7D
39.0%
1Y
191.3%
Ocugen
Market Cap: US$509.1m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.68
7D
2.4%
1Y
73.2%
Arcturus Therapeutics Holdings
Market Cap: US$500.5m
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
ARCT
US$20.48
7D
0.1%
1Y
-19.6%
Lexicon Pharmaceuticals
Market Cap: US$490.6m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
LXRX
US$1.41
7D
6.0%
1Y
-12.4%
REGENXBIO
Market Cap: US$487.5m
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
RGNX
US$9.77
7D
2.4%
1Y
-1.5%
Solid Biosciences
Market Cap: US$480.5m
Develops therapies for neuromuscular and cardiac diseases in the United States.
SLDB
US$5.87
7D
-5.9%
1Y
-11.3%
XOMA Royalty
Market Cap: US$465.9m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$39.23
7D
6.7%
1Y
43.3%
Monte Rosa Therapeutics
Market Cap: US$457.6m
A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
GLUE
US$7.50
7D
13.3%
1Y
39.1%
MoonLake Immunotherapeutics
Market Cap: US$455.3m
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MLTX
US$7.06
7D
-86.9%
1Y
-86.4%
Absci
Market Cap: US$454.5m
Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
ABSI
US$3.13
7D
25.7%
1Y
-17.6%
ADC Therapeutics
Market Cap: US$450.0m
Provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADCT
US$4.00
7D
12.4%
1Y
31.6%
Korro Bio
Market Cap: US$449.7m
A biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
KRRO
US$43.91
7D
14.0%
1Y
33.1%
Immuneering
Market Cap: US$442.7m
A clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
IMRX
US$6.36
7D
-31.1%
1Y
161.7%
I-Mab
Market Cap: US$435.2m
A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
IMAB
US$3.86
7D
8.4%
1Y
164.4%
Autolus Therapeutics
Market Cap: US$433.8m
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
AUTL
US$1.67
7D
7.1%
1Y
-57.9%
Alumis
Market Cap: US$415.2m
A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
ALMS
US$4.06
7D
-1.9%
1Y
-61.0%
Astria Therapeutics
Market Cap: US$410.8m
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
ATXS
US$7.54
7D
3.7%
1Y
-35.2%
4D Molecular Therapeutics
Market Cap: US$405.8m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$8.73
7D
3.4%
1Y
-15.0%
Assembly Biosciences
Market Cap: US$398.3m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$24.61
7D
-4.1%
1Y
68.0%
Evolus
Market Cap: US$397.2m
A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
EOLS
US$6.15
7D
1.0%
1Y
-64.1%
Lineage Cell Therapeutics
Market Cap: US$385.9m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.69
7D
5.6%
1Y
83.3%
Pacific Biosciences of California
Market Cap: US$384.5m
Designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
PACB
US$1.38
7D
10.4%
1Y
-15.9%
Aura Biosciences
Market Cap: US$383.9m
A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
AURA
US$6.15
7D
-0.3%
1Y
-29.6%
Benitec Biopharma
Market Cap: US$368.3m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$14.01
7D
-0.6%
1Y
37.4%
Tvardi Therapeutics
Market Cap: US$365.4m
A clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
TVRD
US$37.82
7D
2.1%
1Y
n/a
Lexeo Therapeutics
Market Cap: US$358.5m
A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
LXEO
US$6.64
7D
1.5%
1Y
-23.9%
DiaMedica Therapeutics
Market Cap: US$355.1m
A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
DMAC
US$6.86
7D
0.1%
1Y
54.2%
Rocket Pharmaceuticals
Market Cap: US$351.8m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$3.16
7D
-4.8%
1Y
-81.4%
Cullinan Therapeutics
Market Cap: US$350.3m
A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
CGEM
US$6.00
7D
-0.5%
1Y
-63.6%